Loading field map
Autoimmunity is the failure of an organism’s immune system to distinguish its own cells and tissues from foreign invaders, leading to an immune response directed against the self. The term is used both for the underlying biological state and for the clinical consequences that arise when that state causes tissue damage. The central puzzle of the field is why a system exquisitely evolved to recognize and eliminate pathogens sometimes turns its considerable destructive power on the body it is meant to protect.
To understand autoimmunity, one must first understand the immune system’s two-part architecture. The innate immune system, the older and faster arm, uses germline-encoded receptors to recognize broad molecular patterns shared by many microbes. The adaptive immune system, which appears only in jawed vertebrates, generates a vast and nearly random repertoire of receptors—B cell receptors (antibodies) and T cell receptors—through gene rearrangement. This randomness is the key to adaptive immunity’s power: it can recognize virtually any pathogen. But it creates an immediate problem. A randomly generated receptor repertoire will inevitably include receptors that bind to the body’s own molecules. The immune system must therefore actively prevent, suppress, or eliminate self-reactive lymphocytes.
The concept of self versus non-self discrimination was formalized in the mid-twentieth century by Frank Macfarlane Burnet, who proposed the clonal selection theory. Burnet argued that lymphocytes are generated with a diverse array of receptors, and that those encountering their specific antigen during development are deleted. Self-reactive cells, encountering self-antigens early in life, would be eliminated, leaving only cells that recognize foreign antigens. This idea, refined with the discovery of the molecular mechanisms of tolerance, remains the foundation of the field. However, it is now clear that self-tolerance is not a single event but a continuous, multi-layered process.
The immune system maintains self-tolerance through several complementary mechanisms, each acting at a different stage of a lymphocyte’s life.
Central tolerance occurs during lymphocyte development in the primary lymphoid organs—the bone marrow for B cells and the thymus for T cells. In the thymus, developing T cells are tested against a display of self-peptides presented by major histocompatibility complex (MHC) molecules. The thymic medullary epithelial cells express a transcription factor called AIRE (autoimmune regulator) that drives the expression of many tissue-specific proteins, allowing developing T cells to be screened against a broad sample of the body’s proteins. T cells that bind too strongly to these self-peptide–MHC complexes are induced to die by apoptosis. This process, called negative selection, eliminates the most dangerous self-reactive T cells. B cells undergo a similar selection in the bone marrow, where those that recognize self-antigens with high avidity are either deleted or edited—their receptor genes are rearranged again to produce a new, non-self-reactive receptor.
Peripheral tolerance operates on mature lymphocytes that have left the primary organs. It is needed because central tolerance is incomplete: not all self-antigens are expressed in the thymus or bone marrow, and some self-reactive cells escape deletion. Peripheral mechanisms include:
The distinction between central and peripheral tolerance is not absolute. Some self-reactive T cells that escape negative selection are converted into regulatory cells in the periphery, and the thymus also exports Tregs. The overall picture is of a redundant, layered system in which any single failure can be compensated by other mechanisms.
When these tolerance mechanisms fail, the result is an autoimmune disease. These conditions are remarkably diverse, differing in the target organ, the type of immune response, and the clinical course. A useful organizing distinction is between organ-specific and systemic autoimmunity, though many diseases do not fit neatly into either category.
Organ-specific autoimmune diseases target a single tissue or organ. Examples include:
Systemic autoimmune diseases involve immune responses against widely distributed self-antigens, often components of the nucleus or cytoplasm present in all cells. The prototypical example is systemic lupus erythematosus (SLE), in which antibodies against DNA, histones, and other nuclear components form immune complexes that deposit in the kidneys, joints, skin, and other organs, causing inflammation and damage. Rheumatoid arthritis, though primarily affecting the joints, is often classified as systemic because it involves immune responses against the Fc portion of immunoglobulin G (rheumatoid factor) and citrullinated proteins, and it can have extra-articular manifestations.
This classification is heuristic rather than absolute. Many organ-specific diseases have systemic features, and systemic diseases often have a dominant organ involvement. The underlying principle is that the clinical phenotype depends on the distribution of the target antigen and the effector mechanisms involved.
Why does autoimmunity develop in some individuals and not others? The answer is multifactorial, involving a combination of genetic susceptibility, environmental triggers, and stochastic events.
Genetic factors are clearly important. Family studies show that first-degree relatives of patients with autoimmune diseases have an increased risk of developing the same or a different autoimmune disease. The strongest genetic associations are with the HLA (human leukocyte antigen) region, which encodes the MHC molecules that present peptides to T cells. Certain HLA alleles are strongly associated with specific autoimmune diseases—for example, HLA-DR4 with rheumatoid arthritis, HLA-DQ2/DQ8 with celiac disease, and HLA-DR3/DQ2 with type 1 diabetes and SLE. The mechanism is thought to involve differences in which self-peptides are presented to T cells during thymic selection and in the periphery. Some HLA alleles may present self-peptides more efficiently, allowing self-reactive T cells to escape negative selection or to be activated later.
Outside the HLA region, genome-wide association studies have identified hundreds of risk variants, most of which lie in genes involved in immune regulation—cytokines, their receptors, co-stimulatory molecules, and components of the innate immune sensing pathways. Each individual variant confers only a small increase in risk, and the cumulative effect of many variants is needed to substantially raise susceptibility. Notably, many risk variants are shared across different autoimmune diseases, suggesting common pathways of immune dysregulation.
Environmental triggers are required because even genetically susceptible individuals do not always develop disease. The most well-established triggers are infections. Several mechanisms have been proposed:
Other environmental factors include smoking (associated with rheumatoid arthritis and SLE), vitamin D deficiency (associated with multiple sclerosis and type 1 diabetes), and the microbiome, which shapes the immune system’s development and may influence tolerance. The hygiene hypothesis—the idea that reduced exposure to infections in industrialized societies leads to an under-educated immune system that is more prone to autoimmunity—remains controversial but has some epidemiological support.
Sex is a major risk factor. Most autoimmune diseases are more common in women, with ratios ranging from 2:1 to 9:1 depending on the disease. The mechanisms are incompletely understood but likely involve sex hormones, which modulate immune responses, and differences in the X chromosome, which contains many immune-related genes. The observation that some autoimmune diseases improve or worsen during pregnancy and that the risk is altered by oral contraceptive use supports a hormonal contribution.
Once self-tolerance fails, the immune system damages tissues through the same effector mechanisms it uses against pathogens. The dominant mechanism varies by disease.
Type II hypersensitivity involves antibodies binding to cell-surface or extracellular matrix antigens, leading to opsonization (tagging for phagocytosis), complement activation, or antibody-dependent cellular cytotoxicity. This is the mechanism in autoimmune hemolytic anemia (antibodies against red blood cells), immune thrombocytopenia (antibodies against platelets), and myasthenia gravis (antibodies against the acetylcholine receptor at the neuromuscular junction).
Type III hypersensitivity involves immune complexes—antibodies bound to soluble antigens—depositing in tissues, particularly in the kidneys, joints, and skin. Complement activation and recruitment of neutrophils cause inflammation and tissue damage. This is the primary mechanism in lupus nephritis and in the vasculitis associated with some systemic autoimmune diseases.
Type IV hypersensitivity is T-cell-mediated. CD4+ helper T cells activate macrophages, which release inflammatory cytokines and reactive oxygen species, while CD8+ cytotoxic T cells directly kill target cells expressing the self-antigen. This is the dominant mechanism in type 1 diabetes, multiple sclerosis, and rheumatoid arthritis.
These mechanisms are not mutually exclusive. Most autoimmune diseases involve both antibody- and T-cell-mediated components, and the relative contribution can change over the course of the disease.
The recognition of autoimmunity as a distinct pathological process emerged gradually. In the early twentieth century, the immunologist Paul Ehrlich coined the term "horror autotoxicus"—the idea that the immune system would never attack the self—which reflected the prevailing belief that autoimmunity was impossible. This view was challenged by the discovery of autoantibodies in patients with certain diseases, such as cold agglutinin disease (antibodies that agglutinate red blood cells at low temperatures) and later in SLE (the LE cell phenomenon, in which neutrophils engulf antibody-coated nuclei).
The modern field was established in the 1950s and 1960s, driven by several key developments. Burnet’s clonal selection theory provided a theoretical framework for understanding self-tolerance. The discovery of immunological tolerance—the observation that animals exposed to foreign antigens during fetal life would not reject those antigens later—demonstrated that self-tolerance was an active, learned process rather than an inherent property of the immune system. The identification of autoantibodies and autoreactive T cells in human diseases established autoimmunity as a real clinical entity.
The 1970s and 1980s saw the elucidation of the cellular mechanisms of tolerance and autoimmunity. The discovery of MHC restriction—the finding that T cells recognize antigen only when presented by self-MHC molecules—explained why the thymus could select for T cells that recognize self-MHC while eliminating those that react too strongly to self-peptides. The identification of regulatory T cells in the 1990s and the subsequent discovery of FoxP3 as their master transcription factor provided a cellular mechanism for peripheral tolerance.
The past two decades have been dominated by the genetic revolution. Genome-wide association studies have identified hundreds of risk loci, and the development of animal models—particularly genetically engineered mice—has allowed the functional testing of candidate genes. Single-cell technologies are now revealing the heterogeneity of immune cells within autoimmune lesions, and the role of the microbiome is an active area of investigation.
Treatment of autoimmune diseases has historically been based on broad immunosuppression. Corticosteroids, which suppress inflammation through multiple mechanisms, remain a mainstay for acute flares. Non-specific immunosuppressive drugs such as methotrexate, azathioprine, and mycophenolate mofetil are used for chronic maintenance. These drugs are effective but carry significant side effects, including increased susceptibility to infections and, with long-term use, an increased risk of certain cancers.
The major therapeutic advance of the past two decades has been the development of biologic agents that target specific components of the immune system. These include:
These targeted therapies are more specific than broad immunosuppression and have improved outcomes for many patients, but they are not curative. They must be taken continuously, and they still carry infection risk because they suppress normal immune function.
A more ambitious goal is antigen-specific immunotherapy—the induction of tolerance to the specific self-antigen involved in the disease, leaving the rest of the immune system intact. Approaches under investigation include oral or nasal administration of the autoantigen, peptide-based vaccines that induce regulatory T cells, and the use of tolerogenic dendritic cells or nanoparticles coated with autoantigen. These strategies have shown promise in animal models but have largely failed in human trials, reflecting the complexity of human autoimmune disease and the difficulty of reversing an established immune response.
Autoimmune diseases collectively affect a substantial fraction of the population—estimates range from 3% to 10% depending on the diseases included and the population studied—and their incidence appears to be increasing in industrialized countries, though the reasons are not fully understood. They are a major cause of morbidity and mortality, particularly in women.
Several fundamental questions remain open. First, what is the initiating event in human autoimmunity? Animal models often use artificial immunization or genetic manipulation, and it is unclear how faithfully they recapitulate the spontaneous onset of human disease. Second, why do some individuals with autoantibodies or autoreactive T cells never develop clinical disease? The presence of autoantibodies is common in healthy individuals, suggesting that additional factors—perhaps local tissue vulnerability or a failure of regulatory mechanisms—are required for disease manifestation. Third, can autoimmunity be reversed, or only suppressed? The current paradigm holds that once the autoimmune response has matured and epitope spreading has occurred, it is self-perpetuating and cannot be eliminated, only controlled.
The field is also grappling with the relationship between autoimmunity and autoinflammation. The latter term refers to diseases caused by dysregulation of the innate immune system, particularly the inflammasome, leading to spontaneous inflammation without evidence of autoantibodies or autoreactive T cells. Diseases such as familial Mediterranean fever and the cryopyrin-associated periodic syndromes are autoinflammatory. The distinction between autoimmunity and autoinflammation is not absolute—some diseases, such as gout and certain forms of juvenile arthritis, have features of both—and the two fields are increasingly seen as ends of a spectrum of immune dysregulation.
Another active area is the role of the microbiome. The gut microbiota shapes the development and function of the immune system, and alterations in its composition have been associated with several autoimmune diseases. Whether these associations are causal, and whether manipulating the microbiome could be therapeutic, remains to be determined.
Finally, the development of precision medicine approaches—using genetic, biomarker, and clinical data to predict disease risk, stratify patients, and select therapies—is a major goal. The heterogeneity of autoimmune diseases, both between patients and within a single patient over time, makes this challenging, but the increasing availability of high-throughput data and computational methods is making it feasible.
Autoimmunity remains a field defined by a central paradox: the immune system, evolved to protect the organism, can become its most dangerous enemy. Understanding how this happens—and how to prevent or reverse it—requires integrating immunology, genetics, microbiology, and clinical medicine. The progress made over the past century has transformed autoimmune diseases from untreatable curiosities into manageable chronic conditions, but the ultimate goal of restoring self-tolerance without compromising protective immunity remains elusive.